Preprint
Review
Enhancing Therapeutic Outcomes with Smart Drug Carriers
This version is not peer-reviewed.
Submitted:
12 March 2025
Posted:
13 March 2025
You are already at the latest version
Abstract
The faster rate in the advancement of drug delivery technology has transformed the practice of modern medicine with greater bioavailability, therapeutic effect, and patient compliance. Low solubility, high clearance, and non-targeted delivery have contributed extensively to conventional drug delivery modes. While overcoming these shortcomings, new drug delivery carriers like liposomes, nanoparticles, and polymer systems are at the forefront as delivery carriers of controlled and targeted therapy.The article addresses the promise, innovation in stimulus-sensitive and ligand-targeted platforms, and translation to industry and clinic for nanoparticle and liposomal drug delivery. Follow-on more recent FDA approvals of other nanomedicine therapeutics show promise and efficacy in infectious disease, management of chronic disease, and cancer. Continuing to revolutionize the era of personalized medicine are the advancement in AI-enabled drug design, nature-inspired delivery platforms, and gene therapy-based carriers.While such monumental leaps have already been made, safety, scale-up, and regulatory challenges must be overcome first before such treatments become the norm around the world. With the synergy of disruptive technologies and best-practice formulation approaches, second-generation drug delivery systems have a generation-defining task to revolutionize therapeutics with more efficient, safer, and patient-more-friendly therapeutics.
Keywords:
Smart drug delivery
; Nanoparticles
; Targeted therapy
; Liposomal carriers
; Precision medicine
Table of Content
1. Introduction
Development of drug delivery system has transformed contemporary medicine with greater therapeutic effectiveness, compliance, and less side effects. The conventional drug administration routes, i.e., oral and intravenous, are usually burdened by issues of low bioavailability, rapid clearance, and non-selective distribution, hence compromising therapeutic efficiency [1]. With the trials to overcome such obstacles, new drug delivery media in the form of nanoparticles, liposomes, and biodegradable polymers have turned to be the preferred drug carriers in a controlled and targeted manner.
They allow drug release in specific locations, site-specific delivery, and reduced systemic toxicity, and are thus invaluable to manage long-term diseases such as cancer and neurodegenerative diseases [2]. Integrating biodegradable polymers with stimulus-responsive carriers has also evolved more intricate mechanisms of drug release, with site-specific stimulation and maximum therapeutic effect.
There is also novel research that has suggested the potential of AI-controlled drug delivery and personalized medicine, where dosing and drug delivery are optimized in accordance to patient profiles [3]. The review describes the design of smart drug carriers, value added to new therapeutics, challenges in clinical translation, and applications of precision medicine.
2. Liposomal and Nanoparticle-Based Drug Delivery
Liposome and nanoparticle delivery systems are precious research reagents for drug solubilization, stabilization, and targeted delivery. These delivery systems enhance pharmacokinetics and biodistribution with access to the target site of action while maintaining therapeutic entities at levels of minimal systemic toxicity [4].
Table. Liposomal and Nanoparticle-Based Drug Delivery Systems.
| Category | Key Features | Examples | Challenges | Reference |
| Liposomal Drug Delivery | Encapsulates hydrophilic & hydrophobic drugs, biocompatible | Doxil (doxorubicin), AmBisome | Stability, immune clearance | [5] |
| PEGylation | Enhances liposome stability, prolongs circulation time | PEGylated liposomes | Complex formulation process | [5] |
| Nanoparticle-Based Drug Delivery | Controlled release, enhanced permeability & retention | Polymeric, metal-based, lipid NPs | Scalability, regulatory approval | [6] |
| Targeted Nanoparticles | Functionalized with ligands/antibodies for active targeting | Brain-targeting nanoparticles | Off-target toxicity, cost | [6] |
3. Challenges in Drug Delivery
Even though drug delivery systems are way ahead by leaps and bounds, they are still confronted with a multitude of challenges during their clinical approval and translation. They range from drug stability, toxicity, biological barriers, to even the challenge of large-scale production [7].
3.1. Biological Barriers and Drug Penetration
One of the biggest challenges of drug delivery is how to overcome physiological barriers such as the blood-brain barrier (BBB), mucosal barriers, and tumor microenvironment to limit drug penetration and bioavailability. Nanoparticle formulations exhibit poor cellular uptake and tissue distribution, affecting therapeutic efficacy [8]. MPS clearance and renal excretion also reduce nanocarrier circulation time, which needs modifications such as PEGylation for enhanced stability and retention [9].
3.2. Toxicity and Immunogenicity
Problems of nanocarrier toxicity and synthetically synthesized nanocarrier immunogenicity are still concerns. Some nanoparticles, such as metal nanoparticles and polymeric nanoparticles, cause oxidative stress, inflammatory responses, and long-term toxicity and limit their therapeutic application in therapy applications. Research aims to utilize biocompatible and biodegradable material to prevent side effects and ensure therapeutic effectiveness [10].
3.3. Manufacturing and Regulatory Hurdles
Scalability, reproducibility, and regulatory issues are the challenges in the bench-to-clinic translation of new drug delivery systems. It is not easy technologically to mass produce homogeneous, stable, and inexpensive nanoparticles or liposomal formulation. Preclinical and clinical trials are stringent by the regulators to screen safety, efficacy, and long-term effects and long development times [11].
Although awe-inspiring, such challenges are no deterrent to everyday research and innovation, more and more providing better and more efficient drug delivery systems.
4. Innovations in Smart and Targeted Drug Delivery
Drug delivery system innovations have developed smart and targeted drug carriers with the ability to enhance the therapeutic impact with reduced toxicity. The smart and targeted drug delivery platform integrates nanotechnology, biomaterials, and molecular targeting strategies in order to enhance drug release and bioavailability [12].
4.1. Stimuli-Responsive Drug Carriers
Current drug delivery systems employ stimuli-responsive materials that release the drug on specific environmental stimuli such as pH, temperature, enzymes, or light. Nanoparticles responsive to the tumor microenvironment, for instance, are engineered to release their payload in response to the low pH of cancer tissue, which is targeted and reduces systemic toxicity [13]. Liposomes have also been engineered that release the drugs in response to hyperthermic temperatures and hence become activated following injection with thermal treatment.
4.2. Ligand-Based Targeting and Theranostic Approaches
The second important characteristic is the development of ligand-functionalized drug carriers that are capable of selectively interacting with the overexpressed receptors on the target diseased cells and thereby conferring high specificity on the drug delivery. For example, folic acid-, transferrin-, or antibody-functionalized nanoparticles have been reported to target cancer cells, enhance the drug uptake and drug efficacy [14].
5. Clinical and Commercial Impact
The use of sophisticated drug delivery systems in the clinical setting has increased the success of therapy by far and impacted the pharmaceutical commercialization. Intelligent drug carriers such as liposomes and nanoparticles have improved the bioavailability of drugs, minimized side effects, and enabled targeted action against infected tissues, thereby being extremely useful in oncology, infection therapy, and treatment of chronic diseases [15].
5.1. Clinical Developments and Therapies Approvals
Increasing numbers of drugs delivered in the form of nanoparticles and liposomes have been approved by regulatory bodies, with the therapeutic efficacy established. Doxil (liposome-encapsulated doxorubicin) for cancer and Abraxane (albumin-bound paclitaxel) for metastatic breast cancer are examples, both showing higher therapeutic efficacy and lower toxicity than traditional formulations [16]. Besides, uses of polymer-drug conjugates and micelle-based delivery systems have presented new fronts of diseases curable, e.g., immunological diseases and central nervous system disorders.
5.2. Commercialization and Market Growth Challenges
Pharmaceutical companies have witnessed increased investment and research grants for nanomedicine funds due to the need for better and targeted therapies. The market for nanomedicine is likely to witness huge growth in personalized medicine and drug delivery systems customized to individuals [17]. But challenges like the high cost of production, cumbersome regulatory routes, and scalability are challenging the process of taking laboratory results to commercially successful products. To overcome these gaps, efficient regulatory mechanisms, inexpensive production methods, and intersectoral convergence among academia, industry, and healthcare communities are the hour of need.
6. Future Directions in Drug Delivery
The present trends in drug delivery technology are moving toward greater precision, flexibility, and integration with digital health technology. Technologies such as AI-aided drug design, bioinspired carriers, and gene-based delivery systems can revolutionize the trend of medical treatment [18].
6.1. Artificial Intelligence and Personalized Medicine
Machine learning and AI are increasingly used to optimize drug design, predict patient response, and tailor treatment regimens. AI, by means of screening high numbers of data points, can be used to identify better drug-carrier interactions, pharmacokinetic optimization, and side effect reduction, to evidence-based, patient-specific therapies [19].
6.2. Bioinspired and Self-Assembling Drug Carriers
Nature-mimicking mimicry drug delivery systems like exosome-based carriers and biomimetic nanoparticles offer highly promising alternatives for artificial nanocarriers. These systems offer enhanced biocompatibility, immune evading capacity, and uptake in cells in a beneficial manner and are used for targeted therapy, especially in cancer and regenerative medicine [20]. The flexibility of self-assembled drug carrier design also enables controlled drug release with adaptive feedback response to the physiological environment and hence enhances the overall therapeutic effectiveness.
6.3. Gene and mRNA-Based Drug Delivery Developments
The success with infectious disease mRNA vaccines has opened up the possibilities of nucleic acid-based drug delivery systems. The technologies are explored by scientists to control genetic diseases, cancer, and neurodegenerative disorders. Transfection of genetic material into target cells via lipid nanoparticles (LNPs) and viral vectors has been proven to cause therapeutic effects in preclinical and clinical trials [21].
6.4. Regulatory and Ethical Issues
In spite of the promising future of drug delivery, long-term safety trials and ethical concerns, as well as regulatory approval processes, are nevertheless key driving forces [22].
These all need to be met head-on by means of concerted inter-disciplinary initiatives, policies, and ongoing innovations in order to take on the challenge and provide future efficacy and safety as part of drug delivery arrangements.
7. Conclusion
Development of drug delivery systems has greatly enhanced the accuracy, effectiveness, and safety of novel therapeutics. Progress from conventional drug delivery systems to novel carriers such as nanoparticles and liposomes has offered improved bioavailability, targeted delivery, and controlled release of drugs with decreased systemic toxicity and increased patient benefit. Improvements in stimulus-responsive carriers and ligand-tagged nanomedicines further enhanced site-specific drug delivery such that treatment options for patients are now customizable. Encouraging as it seems, scalability, manufacturing, and regulative issues pose challenges in large-scale translation to the clinics.
Clinical and commercial acceptance with FDA-approved pharmaceuticals like polymer-based nanomedicine and liposomal nanomedicine drugs have paved the way for greater advances. Convergence of artificial intelligence, bioinspired carriers, and gene-based delivery systems will make precision medicine data-driven, adaptive, and highly effective regimens. All these advances must be brought to the mainstream of clinical practice by virtue of long-term safety, regulatory sanction, and cost-effective production, however.
The next-generation drug delivery will be facilitated through improved biocompatibility, real-time monitoring through the use of theranostic platforms, and patient-specific profile-based targeted therapy. Overcoming current challenges through cross-country collaborations, technology-based innovation, and policy-based regulatory systems, next-generation drug delivery systems will transform therapeutics in practice through improved treatment efficacy, accessibility, and patient-centeredness.
References
- Allen, T.M.; Cullis, P.R. Liposomal drug delivery systems: From concept to clinical applications. Adv. Drug Deliv. Rev. 2013, 65, 36–48. [Google Scholar] [CrossRef] [PubMed]
- Anselmo, A.C.; Mitragotri, S. An overview of clinical and commercial impact of drug delivery systems. J. Control. Release 2014, 190, 15–28. [Google Scholar] [CrossRef] [PubMed]
- Ashutosh, S. Sustainable Drug Delivery Systems with Biodegradable Innovations for Targeted and Efficient Therapy. Preprints 2025. [CrossRef]
- Barua, S.; Mitragotri, S. Challenges associated with penetration of nanoparticles across cell and tissue barriers: A review of current status and future prospects. Nano Today 2014, 9, 223–243. [Google Scholar] [CrossRef] [PubMed]
- Bobo, D.; Robinson, K.J.; Islam, J.; Thurecht, K.J.; Corrie, S.R. R. Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. Pharm. Res. 2016, 33, 2373–2387. [Google Scholar] [CrossRef] [PubMed]
- Danhier, F.; Feron, O.; Préat, V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 2010, 148, 135–146. [Google Scholar] [CrossRef] [PubMed]
- De Jong, W.H.; Borm, P.J.A. Drug delivery and nanoparticles: Applications and hazards. Int. J. Nanomed. 2008, 3, 133–149. [Google Scholar] [CrossRef] [PubMed]
- Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6, 688–701. [Google Scholar] [CrossRef] [PubMed]
- Farokhzad, O.C.; Langer, R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3, 16–20. [Google Scholar] [CrossRef] [PubMed]
- Gupta, A.; Gupta, M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, 26, 3995–4021. [Google Scholar] [CrossRef] [PubMed]
- Hare, J.I.; Lammers, T.; Ashford, M.B.; Puri, S.; Storm, G.; Barry, S.T. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv. Drug Deliv. Rev. 2017, 108, 25–38. [Google Scholar] [CrossRef] [PubMed]
- Koo, H.; Huh, M.S.; Sun, I.C.; Yuk, S.H.; Choi, K.; Kim, K.; Kwon, I.C. In vivo targeted delivery of nanoparticles for theranosis. Acc. Chem. Res. 2011, 44, 1018–1028. [Google Scholar] [CrossRef] [PubMed]
- Kumar, P.; Parmar, B.S. Nanotechnology and its applications in drug delivery: A review. J. Bioequivalence Bioavailab. 2014, 6, 1–5. [Google Scholar]
- Lammers, T.; Kiessling, F.; Hennink, W.E.; Storm, G. Nanotheranostics and image-guided drug delivery: Current concepts and future directions. Mol. Pharm. 2012, 7, 1899–1912. [Google Scholar] [CrossRef] [PubMed]
- Mitragotri, S.; Burke, P.A.; Langer, R. Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies. Nat. Rev. Drug Discov. 2014, 13, 655–672. [Google Scholar] [CrossRef] [PubMed]
- Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2, 751–760. [Google Scholar] [CrossRef] [PubMed]
- Rosenblum, D.; Joshi, N.; Tao, W.; Karp, J.M.; Peer, D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat. Commun. 2018, 9, 1410. [Google Scholar] [CrossRef] [PubMed]
- Sengar, A. Next-Gen Drug Delivery: Redefining Precision, Bioavailability, and Therapeutic Outcomes. Preprints 2025. [Google Scholar] [CrossRef]
- Sengar, A. Smart Drug Delivery: AI, Nanotech & Future Innovations. Preprints 2025. [CrossRef]
- Sengar, A. Advancements in Targeted Drug Delivery: Innovations in Liposomal, Nanoparticle, and Vesicular Systems. Preprints 2025. [CrossRef]
- Shi, J.; Kantoff, P.W.; Wooster, R.; Farokhzad, O.C. Cancer nanomedicine: Progress, challenges and opportunities. Nat. Rev. Cancer 2017, 17, 20–37. [Google Scholar] [CrossRef] [PubMed]
- Sun, T.; Zhang, Y.S.; Pang, B.; Hyun, D.C.; Yang, M.; Xia, Y. Engineered nanoparticles for drug delivery in cancer therapy. Angew. Chem. Int. Ed. 2014, 53, 12320–12364. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Downloads
44
Views
59
Comments
0
Subscription
Notify me about updates to this article or when a peer-reviewed version is published.
MDPI Initiatives
Important Links
© 2025 MDPI (Basel, Switzerland) unless otherwise stated